Ionizing radiation kills cells primarily by generating DNA double-strand breaks, the most lethal form of genetic damage. Cells respond with two principal repair strategies: homologous recombination, which operates in the S and G2 phases of the cell cycle and uses an intact sister chromatid as a template, and non-homologous end joining, which is available throughout the cell cycle and directly ligates broken DNA ends. The Ku heterodimer, composed of the Ku70 and Ku80 proteins, sits at the very front line of non-homologous end joining. It recognizes broken DNA ends within seconds of their formation, encircles the free DNA terminus like a sliding clamp, and recruits the downstream enzymatic machinery needed to process and rejoin the break. Without Ku, double-strand breaks accumulate, chromosomal aberrations multiply, and cells become exquisitely sensitive to radiation.

The new research reveals that the assembly of the Ku70-Ku80 heterodimer itself is not a spontaneous, unregulated event but a process actively promoted by a complex containing TIMELESS and SIRT1. TIMELESS, best known for its role in maintaining circadian clocks and stabilizing replication forks, had previously been implicated in the DNA damage response, but its precise contribution to double-strand break repair remained murky. The study now positions TIMELESS as a scaffold that brings together SIRT1 and Ku70, creating a microenvironment in which Ku70 is kept in a state favorable for pairing with its partner Ku80. SIRT1, an NAD-dependent deacetylase, modifies Ku70 by removing acetyl groups, a chemical change that appears to facilitate the proper folding and interaction of Ku70 with Ku80 and with damaged DNA.

Using a combination of co-immunoprecipitation, proximity ligation assays, and live-cell imaging of DNA repair factor recruitment, the investigators demonstrated that cells lacking TIMELESS or SIRT1 show a marked deficit in Ku heterodimer formation. When the researchers depleted TIMELESS, Ku70 failed to associate efficiently with Ku80, and the recruitment of Ku to laser-induced DNA damage tracks was visibly delayed. The same phenotype emerged when SIRT1 was inhibited pharmacologically or knocked down genetically, indicating that the deacetylase activity of SIRT1 is a functional requirement, not merely a passive component of the complex. Rescue experiments in which wild-type SIRT1 was reintroduced restored Ku assembly, whereas catalytically inactive SIRT1 mutants did not, pinpointing the enzymatic activity as the decisive factor.

The consequences for radiation sensitivity were striking. Cancer cells deficient in TIMELESS or SIRT1 accumulated more residual double-strand breaks after irradiation, displayed elevated levels of chromosome breaks and micronuclei, and died at substantially higher rates following clinically relevant doses of radiation. Conversely, cells engineered to overexpress the TIMELESS-SIRT1-Ku70 module became more resistant, repairing radiation-induced breaks faster and surviving doses that killed their normal counterparts. The effect was specific to the Ku pathway: markers of homologous recombination were largely unaffected, suggesting that the complex operates selectively on non-homologous end joining rather than globally boosting all forms of DNA repair.

What makes this discovery particularly compelling is the cast of characters involved. SIRT1 has long fascinated biologists because of its links to calorie restriction, aging, and metabolism, and pharmacological SIRT1 activators have been pursued as potential anti-aging therapeutics. TIMELESS connects the study to the circadian clock, raising the tantalizing possibility that the daily rhythm of a cell’s repair capacity may be governed, at least in part, by the oscillating availability of this complex. Clinicians have long observed that the timing of radiotherapy within the day can influence outcomes in some cancers, and a molecular bridge between clock proteins and DNA repair machinery offers a plausible mechanistic underpinning for such observations. If TIMELESS abundance or activity fluctuates with the cell’s internal clock, the efficiency of Ku assembly, and therefore of end joining, might fluctuate with it.

For oncology, the immediate implication is that the TIMELESS-SIRT1-Ku70 axis represents a candidate target for radiosensitization. Drugs that disrupt the complex, inhibit SIRT1’s deacetylase activity in tumors, or prevent the recruitment of Ku to broken DNA could strip cancer cells of a key survival advantage and make radiation therapy more effective at lower doses. This matters because dose escalation is often limited by damage to surrounding healthy tissue; a radiosensitizer that preferentially compromises tumor cell repair would widen the therapeutic window. The study’s demonstration that SIRT1 inhibition phenocopies TIMELESS loss is especially encouraging from a translational standpoint, since SIRT1 inhibitors already exist as research tools and are being explored in other disease contexts.

The findings also carry a cautionary note for interpreting tumor biology. High levels of TIMELESS have been reported in several malignancies and have been associated with poor prognosis, an observation often attributed to the protein’s role in supporting replication stress tolerance and cell proliferation. The new work adds a second, complementary explanation: tumors that overexpress TIMELESS may also be intrinsically more resistant to radiotherapy because their Ku assembly machinery runs at full throttle. This could help explain why some patients with seemingly similar tumors respond dramatically differently to the same radiation regimen, and it suggests that TIMELESS expression levels might serve as a biomarker for predicting radiosensitivity and guiding treatment decisions.

As with any mechanistic study, important questions remain. The precise structural details of how TIMELESS docks onto Ku70 and how SIRT1’s deacetylation of Ku70 alters the heterodimer’s DNA-binding properties will require biochemical and structural characterization. It is also not yet clear whether the complex acts at the break site itself or in the nucleoplasm before Ku ever encounters damaged DNA, and whether additional factors participate in the assembly process. Translating the findings into the clinic will demand evidence that the axis operates in human tumors in vivo and that its disruption does not catastrophically sensitize normal tissues, which also rely on Ku-mediated repair to survive radiation. Nonetheless, by illuminating a previously hidden regulatory step in one of the cell’s most fundamental repair pathways, the study opens a concrete new avenue for making radiation therapy work harder against cancer, and it reinforces a growing theme in modern oncology: the most effective treatments may come not from hitting tumors harder, but from quietly dismantling the molecular machinery that lets them endure.

Subject of Research: A TIMELESS-SIRT1-Ku70 protein complex that promotes Ku heterodimer assembly and confers radioresistance to cancer cells through enhanced non-homologous end joining DNA repair.

Article Title: A TIMELESS-SIRT1-Ku70 complex confers radioresistance to cancer cells by promoting Ku heterodimer assembly

Article References: A TIMELESS-SIRT1-Ku70 complex confers radioresistance to cancer cells by promoting Ku heterodimer assembly. (n.d.). https://doi.org/10.1038/s41420-026-03363-w

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03363-w

Keywords: TIMELESS, SIRT1, Ku70, Ku80, DNA double-strand breaks, non-homologous end joining, radioresistance, radiation therapy, DNA repair, circadian clock, cancer, radiosensitization